Vapotherm(R) Launches New Device, Precision Flow(TM)
STEVENSVILLE, Md., Nov. 29 /PRNewswire-USNewswire/ -- Vapotherm, the global leader in High Flow Oxygen Therapy products, will introduce a new respiratory care device at the AARC annual conference in Orlando, Florida on December 1, 2007. Vapotherm's Precision Flow(TM) is the first high flow therapy device to integrate humidification, gas blending, flow control, and full alarm functionality into a single device for the delivery of nasal cannula inspired gases. The company has submitted and is awaiting 510(k) clearance for the new product from the FDA.
"Vapotherm literally established the High Flow Oxygen Therapy category and the launch of Precision Flow(TM) not only reinforces our leadership role in the industry but also illustrates our dedication to developing innovative respiratory devices that help healthcare professionals improve the quality of life for their patients," said Robert Storey, President and CEO of Vapotherm. "The AARC meeting is the ideal venue for us to introduce the new technology and get valuable feedback from the respiratory community."
The company's current device, the 2000i, is used in hundreds of hospitals throughout the US. With Precision Flow(TM), the respiratory community will have a new option in high flow therapy that includes broader functionality, additional safety features and ease of use. "We developed Precision Flow(TM) with extensive input from our respiratory customers and we believe the device will meet their stated requirements for performance, safety and cost-effectiveness," said Kevin Thibodeau, Vice President of Sales and Marketing.
Precision Flow(TM) will be unveiled by Vapotherm at Booth #1337 during the AARC annual conference in Orlando, Florida in December. The device is pending FDA 510(k) clearance and is not currently available for sale in the US.
Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and home care use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive technologies for respiratory therapy, especially for the treatment of chronic lung and acute breathing disorders. For more information, visit www.vtherm.com.
Amy Elias/Brian Johnson
SOURCE Vapotherm, Inc.
You May Also Like